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ABSTRACT
The development of new methods for gene addition
to mammalian genomes is necessary to overcome
the limitations of conventional genetic engineering
strategies. Although a variety of DNA-modifying
enzymes have been used to directly catalyze the in-
tegration of plasmid DNA into mammalian genomes,
there is still an unmet need for enzymes that target a
single specific chromosomal site. We recently en-
gineered zinc-finger recombinase (ZFR) fusion pro-
teins that integrate plasmid DNA into a synthetic
target site in the human genome with exceptional
specificity. In this study, we present a two-step
method for utilizing these enzymes in any cell type
at randomly-distributed target site locations. The
piggyBac transposase was used to insert recombin-
ase target sites throughout the genomes of human
and mouse cell lines. The ZFR efficiently and specif-
ically integrated a transfected plasmid into these
genomic target sites and into multiple transposons
within a single cell. Plasmid integration was depend-
ent on recombinase activity and the presence of re-
combinase target sites. This work demonstrates the
potential for broad applicability of the ZFR technol-
ogy in genome engineering, synthetic biology and
gene therapy.
INTRODUCTION
Technologies for introducing gene sequences into mam-
malian cells are central to numerous applications in medi-
cine, biopharmaceutical production and mechanistic
studies of gene function. Similarly, the burgeoning ﬁelds
of synthetic biology and metabolic engineering are
founded on complex genetic engineering of cell systems.
Ideally, these applications would involve the addition of
genes to speciﬁc sites in the genome that facilitate desir-
able gene expression characteristics and minimize aberrant
effects on the cell. However, current methods for chromo-
somal gene addition use viral delivery vehicles or
DNA-modifying enzymes that integrate DNA sequences
semi-randomly in the billions of base pairs of mammalian
genomes. This approach has the potential to disrupt
endogenous gene sequences that leads to unpredictable
consequences on cell activity (1). Additionally, isogenic
cell lines must be clonally derived after gene addition to
ensure robust and uniform levels of gene expression across
the cell population. Methods for reproducibly integrating
genes at speciﬁc genomic target sites would overcome
these challenges and enable robust genome manipulation
for diverse ﬁelds of biotechnology and biological research.
Retroviral and lentiviral vectors are the conventional
delivery vehicles for gene addition to mammalian genomes.
These vectors integrate semi-randomly into the genome
with a preference for promoters or intragenic regions of
actively transcribed genes (2,3). In several gene therapy
clinical trials, integration of the strong viral promoters
nearby proto-oncogenes has led to gene deregulation and
clonal expansions (4–6). Consequently, these vectors are
not useful for applications that require targeted gene
addition. The piggyBac and Sleeping Beauty transposon
systems have both been used to integrate genes into mam-
malian genomes in vitro and in vivo (7–9). Because the
transposon systems do not contain the strong viral pro-
moters, it is anticipated that activation of nearby onco-
genes will be unlikely. Additionally, Sleeping Beauty, and
to a lesser extent piggyBac, appear to integrate more
randomly into the genome than g-retroviral vectors and
do not show as strong a preference for integration into
genes (8,10,11). However, transposition into an oncogene
or tumor suppressor and subsequent insertional mutagen-
esis has been demonstrated in genetic screens that are
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studies have attempted to direct gene transposition by
these enzymes to genomic target sites by the fusion of
sequence-speciﬁc DNA-binding proteins, the majority of
gene addition events in these systems are still random
(14,15).
In contrast to the random addition of genes by viral
vectors and transposases, the Cre and Flp recombinases
catalyze the exchange of DNA strands between loxP and
FRT sequences, respectively (16,17). Cre and Flp have
both been used to target plasmid integration into loxP
or FRT sites that have been pre-introduced into mamma-
lian cell genomes (17,18). The efﬁciency of Flp-mediated
plasmid integration is comparable to random plasmid in-
tegration (17,19). Therefore additional selection or screen-
ing steps are necessary to ensure site-speciﬁc integration.
Cre expression is toxic to mammalian cells (20,21) and can
lead to chromosomal rearrangements by reacting with
off-target pseudo-loxP sites present in the human genome
(22,23). Similarly, the phage-derived integrase phiC31
catalyzes the integration of a transfected plasmid into
pseudo-recognition sites in the human genome (24,25).
Thorough characterization of the pseudo-recognition
sites in human cells identiﬁed over 100 distinct genomic
integration sites, with a slight preference for integration
into intragenic regions (26). Chromosomal rearrange-
ments have also been observed in human cells following
phiC31 expression (27,28). Although recent in vivo safety
studies suggest that phiC31 expression does not lead to
oncogenic insertional mutagenesis (29), there remains a
clear need for enzymes with strict DNA-binding
domains that recognize unique sites within mammalian
genomes.
The Cys2-His2 zinc-ﬁnger domain is the most common
DNA-binding motif in the human proteome. A single zinc
ﬁnger contains  30 amino acids and typically functions by
binding three consecutive base pairs of DNA via inter-
actions of a single amino acid side chain per base pair
(30). The speciﬁcity of particular zinc ﬁngers for the 64
possible nucleotide triplets has been examined extensively
through site-directed mutagenesis, rational design and the
selection of large combinatorial libraries (31–33).
The modular structure of the zinc-ﬁnger motif permits
the fusion of several domains in series, allowing for the
recognition and targeting of extended sequences in mul-
tiples of 3 nucleotides (34). It is now possible to design
synthetic zinc-ﬁnger proteins to bind practically any target
site in the human genome (35,36).
These targeted DNA-binding proteins can be fused to
enzymatic domains to direct enzyme activity to speciﬁc
sites in the genome. This approach has been most prom-
inently exempliﬁed by the development of zinc-ﬁnger nu-
cleases (ZFNs), in which the synthetic zinc-ﬁnger protein
is fused to the catalytic domain of the FokI restriction
endonuclease (37). When expressed within mammalian
cells, ZFNs cleave DNA to create a double-strand break
at a targeted genomic locus (37). This DNA cleavage
stimulates DNA repair pathways and increases the efﬁ-
ciency of homologous recombination at the site by several
orders of magnitude, which otherwise occurs below back-
ground levels of random plasmid integration in human
cells. This method has been used to incorporate gene se-
quences at speciﬁc locations in the genomes of cells from a
variety of species, including human cell lines and embry-
onic and adult stem cells (37). However, the potential for
off-target DNA cleavage, the induction of the DNA-
damage response pathway and the associated genotoxicity
that has been often observed with these enzymes remain
concerns for this method (37–39).
Inspired by the success of the ZFN technology, we have
recently developed zinc-ﬁnger recombinases (ZFRs) to au-
tonomously perform precise gene addition to the human
genome without cleaving genomic DNA and activating
the DNA damage response pathway (40). ZFRs are a
fusion of a synthetic zinc-ﬁnger protein and the catalytic
domain of a serine recombinase (41,42). For the chromo-
somal integration of plasmid DNA, the designed zinc-
ﬁnger domain binds to speciﬁc target sites in the genome
and the plasmid, and the recombinase domain catalyzes
the exchange of DNA strands (40). In the original dem-
onstration of this approach, a single model recombinase
target site was introduced into a speciﬁc, but unknown,
chromosomal location in the human HEK-293 cells using
the Flp-In
TM cell lines and reagents from Invitrogen. We
demonstrated that ZFRs could target plasmid integration
into this site with >98% speciﬁcity (40). This speciﬁc in-
tegration occurred only if the correct target site was pre-
sent and the DNA-binding domain of the ZFR contained
at least three zinc-ﬁnger motifs. In the current study, we
sought to evaluate the general applicability of this
system by investigating ZFR-mediated plasmid integra-
tion into target sites in diverse regions of the genome
and in a variety of cell lines. The piggyBac transposon
system was used to distribute ZFR recognition sites
randomly throughout the genome in a population of
cells. Genomic integration of a transfected plasmid was
dependent on both an active ZFR and the presence of
ZFR target sites in the genome, demonstrating the strin-
gent selectivity of these enzymes. ZFR and piggyBac
activity were both dependent on cell type. Clonal
analysis showed that the vast majority of stably trans-
fected cells contained integration events at the intended
target site, and in some instances the ZFR was able to
integrate plasmids into multiple transposon target sites
within the same cell. These results support the broad
utility of the ZFR technology and suggest possibilities
for engineering of isogenic cell lines and stem cell-based
gene therapies.
MATERIALS AND METHODS
Plasmids
The plasmids pTpB and pCMV-pB were provided by
Matthew H. Wilson (8). The pTpB plasmid contains the
piggyBac transposon, which carries a kan
R/neo
R cassette
driven by the SV40 promoter and a p15A origin of repli-
cation for propagation in Escherichia coli. pCMV-pB
carries the expression cassette for the piggyBac trans-
posase. For our piggyBac expression vector, the
piggyBac transposase was PCR ampliﬁed and inserted
into a pcDNA3.1-Zeocin ZFR expression plasmid (40)
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44-bp ZFR target site was added to pTpB by PCR amp-
liﬁcation of a 1109-bp fragment containing the C.20G
ZFR target sequence and a neighboring promoterless
EGFP transgene from the pcDNA5/FRT-EGFP-C.20G
plasmid (40) and ligation into the BamHI site in pTpB
downstream of the kan
R/neo
R cassette in the piggyBac
transposon. The luciferase-encoding piggyBac transposon
was created by removing the kan
R/neo
R cassette in pTpB
by digestion with BglII and SacII and ligation of a CMV
promoter driving the luciferase gene into these sites. The
ZFR expression plasmid pcDNA3.1-Zeocin-GinC4 and
the C.20G-Puro ZFR donor plasmid carrying the puro
R
cassette have been described previously (40). The
luciferase-encoding ZFR donor plasmid was created by
removing the puro
R gene from the C.20G-Puro donor
plasmid (40) by digestion with HindIII and NheI and ligat-
ing the luciferase gene into these sites, under the control of
the SV40 promoter. All vector sequences were conﬁrmed
by DNA sequencing.
Transposition and plasmid integration
All cell lines were cultured in DMEM, 10% fetal bovine
serum, 100U/ml penicillin G sodium and 100mg/ml
streptomycin sulfate in a humidiﬁed 5% CO2 atmosphere
at 37 C. All cell culture media components and reagents
were obtained from Invitrogen unless otherwise noted.
Transfections were performed with Lipofectamine 2000
(Invitrogen) according to the manufacturer’s instructions.
Twenty-four hours prior to transfection, 100000 cells
were plated into 24-well plates. For piggyBac-mediated
transposition, cells were transfected with 250ng of pTpB
and 250ng of pcDNA3.1-Zeocin-piggyBac or control
pcDNA3.1-Zeocin plasmid (no insert). For ZFR-
mediated donor plasmid integration, cells were transfected
with 50ng donor plasmid and 500ng of control
pcDNA3.1-Zeocin plasmid (no insert), pcDNA3.1-
Zeocin-ZFR
S9A, or pcDNA3.1-Zeocin-ZFR.
For colony-counting assays, 10% of the transfected cell
population was moved to one well of a six-well plate at
3 days post-transfection. The following day, cell culture
media was exchanged with media containing 800mg/ml
G418 sulfate and/or 2mg/ml puromycin as appropriate.
Approximately 14 days later, cells were stained with
crystal violet solution and colony number was determined
by automated counting using a GelDoc XR imaging sys-
tem with Quantity One 1-D analysis software (Bio-Rad).
Reported colony numbers have been multiplied by a
factor of ten to account for the initial 1:10 cell division.
For luciferase assays, cells were continuously cultured in
the absence of selection with passaging every 3–5 days. At
each passaging, cell samples were harvested and frozen. At
the conclusion of the experiment, samples were thawed
and assayed for luciferase activity with the Luciferase
Reporter Assay System (Promega) according the manu-
facturer’s instructions using a Veritas Microplate
Luminometer (Turner Biosystems) equipped with
injectors.
Genomic DNA isolation and analysis
Genomic DNA was puriﬁed with QIAamp DNA Blood
kits (Qiagen) from G418
R/puro
R polyclonal cell popula-
tions or monoclonal populations derived by limiting dilu-
tion. Genomic DNA was used as template in PCR reactions
with primer combinations that ampliﬁed the unmodiﬁed
ZFR target site (pTpB-prim1 & pTpB-prim2), the integra-
tion of the donor plasmid into the ZFR target site in the
forward orientation (donor-prim1 & pTpB-prim2), or the
integration of the donor plasmid into the ZFR target site
in the reverse orientation (donor-prim1 & pTpB-prim1).
Primer binding sites are indicated in Figure 1A and C.
Primer sequences are: pTpB-prim1: 50-TTTTCCGGGAC
GCCGGCTGG-30; pTpB-prim2: 50-CTTGTCGGCCAT
GATATAGACG-30; donor-prim1: 50-TGACGTCAATG
ACGGTAAATGG-30.
Southern blots were performed using standard proced-
ures. Brieﬂy, 1mg of genomic DNA was digested with
HindIII (Figure 1A and C) for 4h. Digested DNA was
separated on a 1% agarose gel by electrophoresis. The gel
was washed and blotted onto a membrane (GeneScreen
Plus, Perkin Elmer) overnight using an upward capillary
transfer. The membrane was crosslinked with UV light for
30s and dried on ﬁlter paper. An 800-bp probe of the neo
R
gene in the pTpB plasmid was generated by PCR with the
primers 50-ATGATTGAACAAGATGGATTGC-30 and
50-TCGTCAAGAAGGCGATAGAA-30 and labeled with
32P using the PrimeIT II kit (Stratagene) according to
manufacturer’s instructions. The blot was pre-hybridized
in MiracleHyb buffer (Stratagene). Following overnight
hybridization with the radiolabeled probe at 65 Ci na
rotary hybridization oven, blots were washed twice in
solution A (2  SSC, 0.1% SDS) and twice in solution B
(0.01  SSC, 0.1% SDS) for 15min at 50 C. Labeled blots
were then exposed to a phosphorimager cassette
(Molecular Dynamics) for 14 days and visualized on a
Storm840 phosphorimager (GE Healthcare).
Plasmid rescue
Genomic DNA (10mg) was digested with NheI and XbaI,
which have compatible 50 CTAG overhangs. NheI cut
inside the donor plasmid, and NheI or XbaI were expected
to cut within the neighboring genomic DNA outside of the
50-end of the piggyBac transposon. Digested DNA was
puriﬁed by ethanol precipitation and ligated in dilute con-
ditions of 300ml total ligation volume to favor self-
ligation. The resulting plasmid contained the kan
R gene
and p15A replication of origin from the pTpB transposon.
The DNA was concentrated by ethanol precipitation, re-
suspended in water and electroporated into XL1 Blue
E. coli and plated onto kanamycin-containing LB agar
plates. Colonies were screened by colony PCR for plasmids
that contained the donor plasmid sequence integrated into
the piggyBac transposon ( 10% of all colonies), rather
than only the transposon. Plasmid DNA from positive
colonies was puriﬁed by miniprep (Qiagen) and sequenced
with primers extending from both the 50 terminal inverted
repeat (TR) of the transposon and the puro
R gene within
the donor plasmid (Figure 6).
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Data are presented from representative experiments as the
mean of triplicate samples±standard error of the mean
(mean±SEM). Statistical analyses for colony number
assays included two-sided, two-sample Student’s t-test
assuming equal variances (Figure 2A) or two-way
ANOVA accounting for both cell type and treatment
(Figure 3A). Statistical analyses for luciferase assays
included two-way ANOVA accounting for both time
and treatment, for which only P-values with respect to
A
B
C
D
Figure 1. (A) Schematic of plasmids used for piggyBac-mediated transposition. (B) Schematic of plasmids used for ZFR-mediated integration of the
donor plasmid. (C) Schematic of predicted results of targeted donor plasmid integration into the piggyBac transposon in forward or reverse
orientations. Small black arrows indicate the positions of PCR primers used for detection of targeted integration. HindIII restriction sites and
fragment sizes indicate expected results of Southern blot analysis with a probe against kan
R/neo
R.( D) Experimental design. Cell lines were ﬁrst
co-transfected with a plasmid encoding the piggyBac transposase (pCMV-pB) and a plasmid carrying a piggyBac transposon that contains a ZFR
target site and neo
R/kan
R cassette (pTpB). Random transposition was used to generate a polyclonal cell population with ZFR target sites distributed
throughout the genome. Following selection of neo
R cells, these populations were co-transfected with a ZFR expression plasmid (pCMV-ZFR) and a
donor plasmid containing a ZFR recognition site and puro
R cassette to assess targeted plasmid integration into the piggyBac transposon by the ZFR.
Nucleic Acids Research, 2011,Vol.39, No. 17 7871treatment were reported (Figures 2B and 3B). In order to
make the variance independent of the mean, statistical
analysis of luciferase assays was performed following loga-
rithmic transformation of the raw data. Analyses were
performed with Microsoft Ofﬁce Excel 2007 with
a=0.05.
RESULTS
In order to create a heterogeneous population of poly-
clonal cells carrying ZFR target sites, the piggyBac trans-
poson system was used to randomly distribute target sites
throughout the genomes of several cell lines (Figure 1).
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transposon in the pTpB plasmid, which also contains a
kanamycin/neomycin resistance (kan
R/neo
R) cassette and
a p15A origin of replication for propagation in E. coli (8).
This modiﬁed transposon was co-transfected with control
plasmid DNA or a plasmid encoding the piggyBac
transposase into four cell lines: human embryonic kidney
(HEK293) cells, human epithelial cervical cancer (HeLa)
cells, human hepatocarcinoma (HuH-7) cells and NIH3T3
mouse embryonic ﬁbroblasts. Cells in which the trans-
poson was stably integrated into the genome were neomy-
cin resistant and selected by growth in the presence of
antibiotic G418. The number of G418-resistant (G418
R)
cell colonies was used as a measure of transposase activity
(Figure 2A). The presence of the transposase signiﬁcantly
increased the number of stable integrants, ranging from
9-fold in HuH-7 cells to 58-fold in HEK293 cells. The level
of background integration of plasmid DNA, the
fold-increase of G418
R colonies upon the addition of
transposase, and the total number of G418
R colonies
varied greatly among cell lines, as noted previously (43).
To monitor stable transposition in the absence of select-
ive pressure, the neo
R gene in the piggyBac transposon
was replaced with a luciferase gene. This plasmid was
co-transfected into each cell line with control plasmid
DNA or the transposase expression plasmid and samples
were harvested over a time course of 40 days to monitor
stable luciferase gene expression (Figure 2B). In the
absence of transposase, luciferase levels dropped precipi-
tously over 10–15 days post-transfection as a result of epi-
somal plasmid degradation and dilution during cell
division. Luciferase activity stabilized at a low level after
this period. In contrast, addition of the transposase re-
sulted in sustained gene expression at signiﬁcantly higher
levels for the duration of the experiment in all cell lines.
PiggyBac transposes semi-randomly into mammalian
genomes at TTAA sequences (8). Consequently the
G418
R cell populations from the samples transfected
with both transposase and transposon were heteroge-
neous; each original cell incorporated one or more trans-
posons into different locations in its genome (44).
Therefore these polyclonal cell populations were used to
assess the ability of the ZFR to integrate plasmid DNA
into different genomic loci in various cell types (Figure 1).
The ZFR used for this study, GinC4, is a fusion of the
catalytic domain of the Gin invertase and a four-ﬁnger
designed zinc-ﬁnger protein (40). For this experiment,
both the parental cell lines and the G418
R transposon-
modiﬁed cell lines (Figure 2A) were co-transfected with
a donor plasmid containing both a ZFR target site and
a puromycin-resistance (puro
R) cassette and either control
DNA, a plasmid that expresses a catalytically inactive
ZFR (ZFR
S9A), or a plasmid that expresses the ZFR. At
3 days post-transfection, the cells were moved to
puromycin-containing media for 14 days and the level of
plasmid integration into the genome was measured as
the number of puro
R cell colonies (Figure 3A). The
addition of active ZFR to the transposon-modiﬁed cells
increased the level of plasmid integration relative to
cells without ZFR, cells with inactive ZFR and cells
with ZFR but without transposon target sites. Similar to
piggyBac-mediated transposition, the level of background
plasmid integration, the fold-increase of puro
R colonies
upon the addition of ZFR, and the total number of
puro
R colonies varied greatly among cell lines. The differ-
ences in plasmid integration levels between the parental
cell lines and the transposon-modiﬁed cell lines when
both were treated with donor plasmid and active ZFR
was particularly notable in the NIH3T3, HeLa and
HuH-7 cell lines. The selectivity of the ZFR was such
that in the absence of the appropriate 44-bp target site,
the level of ZFR-mediated recombination into any of the
>3 billion base pairs of the human or mouse genomes was
not signiﬁcantly higher than background plasmid integra-
tion. It is unclear why there was a measurable increase in
plasmid integration in the HEK293 cell line upon the
addition of active ZFR despite the absence of transposon
target sites, although there was a signiﬁcant increase when
the transposon was present. It is also noteworthy that
binding of the catalytically inactive ZFR
S9A to the target
sites with intact zinc-ﬁnger proteins led to a moderate
increase in colony numbers in HEK293 cells but did not
have any effect on plasmid integration in the other three
cell types. Importantly, we have previously validated that
the ZFR
S9A mutant is catalytically inactive in a high-
throughput excision assay in E. coli (45). Therefore the
mechanism for ZFR
S9A-mediated stable transfection in
HEK293 cells is unknown, although it is clear that none
of the plasmid was correctly targeted to the transposon
(Figure 4). It is possible that binding of the ZFR to its
target site on the plasmid may modify its stability in the
absence of any catalytic activity.
In order to measure the time course of gene expression
following ZFR-mediated plasmid integration in the ab-
sence of the selective pressure of antibiotics, the puro
R
gene in the donor plasmid was replaced with the luciferase
gene. G418
R HEK293 cells were co-transfected with the
luciferase-encoding donor plasmid and either control
DNA, the ZFR
S9A expression plasmid, or the active
ZFR expression plasmid. Cell samples were collected at
various time points up to 30 days post-transfection and
assayed for luciferase activity (Figure 3B). Cells treated
with donor plasmid and ZFR showed >10-fold increases
in the levels of stable gene expression relative to cells
treated with donor plasmid only. The expression of the
inactive ZFR
S9A led to an intermediate level of stable
luciferase expression in HEK293 cells similar to the
colony formation assay (Figure 3A).
In order to determine whether the plasmid integration
events mediated by the ZFR were correctly targeted to the
transposon, genomic DNA was puriﬁed from the poly-
clonal puro
R cell populations and assayed by PCR
(Figure 4). PCR primers were used that amplify the un-
modiﬁed transposon or the ZFR donor integrated into the
transposon in either forward or reverse orientations
(Figure 1A and C) (40). Although these cell populations
were polyclonal with respect to transposon integration
sites, the PCR ampliﬁcation should occur independently
of chromosomal location. The PCR products correspond-
ing to the correct plasmid integration events in forward
and reverse orientations were present only in samples con-
taining both the donor and an active ZFR. Unmodiﬁed
Nucleic Acids Research, 2011,Vol.39, No. 17 7873transposons were detected in all cell populations, which is
not surprising given that it is possible for >15 transpos-
ition events to occur in a single cell (44) and cells would be
selected in this assay if the plasmid integrated into at least
one of these transposons. Although most samples from
ZFR-treated HeLa cells were positive for site-speciﬁc
plasmid integration, results were inconsistent due to low
numbers of puro
R colonies (Figure 3A) and overgrowth of
the cell population by small numbers of rapidly expanding
colonies. Therefore results obtained from experiments
with HeLa cells are not shown.
Although the genomic PCR of the polyclonal popula-
tion indicated that site-speciﬁc integration events were
present within the sample, how frequently these events
occurred was unknown. Therefore monoclonal cell popu-
lations were derived from single cells of the puro
R cultures
that had been treated with donor and active ZFR to de-
termine the overall level of speciﬁcity in the population
(Figure 5). The genomic DNA from these clonal popula-
tions was analyzed by PCR for targeted integration events
(Figure 5A). Except for one aberrant HEK293 clone, all of
the clonal samples contained transposons that had not
been modiﬁed by plasmid integration, which could be pre-
dicted by previous studies showing multiple transpositions
per cell (44). Of 24 HEK293 clones, only ﬁve clones had
no targeted integration events, including the single clone
in which the unmodiﬁed transposon was not detectable.
These clones represent cells in which the puro
R donor plas-
mid integrated at an off-target site. Thirteen clones had
only forward integrations, four clones had only reverse
integrations, and two clones contained both reverse and
forward integrations. All 20 of the HuH-7 clones and 19 of
the 20 NIH3T3 clones contained targeted integration
events, and the vast majority of these (17/20 NIH3T3
and 17/20 HuH-7 clones) contained both forward and
reverse integrations. The PCR products from selected
samples were sequenced to conﬁrm the accurate junction
of the transposon and donor plasmid. Southern blots of
the genomic DNA from a subset of the HEK293 clones
veriﬁed the PCR results and validated the PCR-based
method for detecting clones with forward and/or reverse
integration orientations (Figure 5B).
The chromosomal locations of representative ZFR-
mediated integration events were determined to conﬁrm
that donor plasmid integration occurred at multiple
chromosomal locations (Figure 6). A plasmid rescue assay
was performed in which the genomic DNA of the poly-
clonal puro
R/G418
R ZFR-treated HEK293 cells was
digested with the restriction enzymes NheI, which cuts
inside the donor plasmid and XbaI, which is expected to
cut in the chromosomal DNA near the transposon inte-
gration site. Self-ligation of the digestion products resulted
in a new plasmid that contained sequences from the
piggyBac transposon, donor plasmid and ﬂanking chromo-
somal DNA. This plasmid can be transformed and pro-
pagated in E. coli because of the kan
R cassette and p15A
origin of replication within the transposon. Plasmids con-
taining the donor fragment were distinguished from
non-targeted transposons by colony PCR and sequenced
with transposon- and donor-speciﬁc primers to determine
chromosomal location. Representative sequences show
that the piggyBac target sites were on different chromo-
somes (Figure 6). The recovered events occurred within
genes, which is a preferred region for piggyBac transpos-
ition (8). These results show that the ZFR was active at
several chromosomal locations in human cells.
DISCUSSION
This study demonstrates the ability of ZFRs to direct the
targeted chromosomal integration of a plasmid at speciﬁc
recognition sites distributed throughout human and
mouse genomes in several cell types. As measured by the
fraction of stable transfectants containing successfully
targeted integration events (Figure 5A), ZFR speciﬁcity
is signiﬁcantly greater than any of the enzyme- or
viral-mediated vector integration strategies described to
date. In our previous study using an isogenic HEK293
cell line with a ZFR target site at a single accessible
locus, we observed targeted integration in 55 of 56
clones (40). We have now observed similarly high levels
of speciﬁcity into polyclonal targets in 19/24, 19/20 and
20/20 clones for HEK293, NIH3T3 and HuH-7 cells, re-
spectively (Figure 5A), as well as detectable site-speciﬁc
integration in HeLa cells (Figure 4). For comparison, a
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Donor
Only
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Donor
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Only
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Only
Donor
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Donor
& ZFR
Reverse
Forward
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Forward
Figure 4. Speciﬁcity of ZFR-mediated plasmid integration. Genomic
DNA from polyclonal G418
R/puro
R cell populations that had been
transfected with donor plasmid and control (empty), ZFR
S9A,o r
ZFR expression plasmid was analyzed by PCR. PCR primer combin-
ations ampliﬁed either the unmodiﬁed ZFR target site on the piggyBac
transposon or the integration of the donor plasmid at this site in either
forward or reverse orientations. Targeted plasmid integration was
detected only in samples treated with the ZFR.
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Figure 5. Clonal analysis of ZFR-mediated plasmid integration events. Single cell colonies were isolated by limiting dilution from polyclonal G418
R/
puro
R cell populations that had been transfected with donor plasmid and ZFR expression plasmid. (A) Genomic PCR was used to detect the
unmodiﬁed ZFR target site on the piggyBac transposon and/or the integration of the donor plasmid at this site in either forward or reverse
orientations. (B) Southern blot of unmodiﬁed HEK293 cells, G418
R HEK293 cells containing the piggyBac transposon, and the ﬁrst six G418
R/
puro
R clonal HEK293 cell populations was performed with a probe against the neo
R cassette. Distinct bands correspond to the unmodiﬁed trans-
poson and forward and reverse orientations of the correctly targeted donor plasmid integration (Figure 1A and C) and coincide with the PCR results
in (A).
Figure 6. Mapping the chromosomal locations of donor plasmid integrations into the transposon target site. Genomic DNA of the polyclonal
G418
R/puro
R HEK293 cell populations was digested with NheI and XbaI, circularized by ligation and transformed into E. coli. Puriﬁed plasmid was
sequenced by reverse and forward primers that bind to the transposon and donor plasmid, respectively, to ensure recovery of correctly targeted
transposons. The recovered sequences were intragenic, which is a favored location for piggyBac transposition (8). Gene names and chromosomal
locations are indicated to the right of the corresponding sequencing results. The positions of sequencing primers are indicated with black arrows. The
underlined TTAA and CTAG correspond to the site of piggyBac transposition and the NheI/XbaI compatible 50 overhang, respectively.
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phiC31 integrase into the genome of HEK293 cells showed
only 14/96 clones contained site-speciﬁc integration events
(24), with the other 82 clones likely containing integration
events at any of the other >100 genomic sites that are also
recognized by this enzyme (26).
The high frequency of targeted integration events in the
clonal cell populations (Figure 5) does not eliminate
the possibility that off-target integration events also
occurred in these cells. However, given that only  1%
of the total transfected cell population contains an inte-
gration event (40), we expect it is unlikely that high levels
of ZFR-mediated off-target integration are occurring.
Furthermore, ZFR activity increased  3-fold when the
transposon target site was pre-introduced in the genome
of NIH3T3, HeLa and HuH-7 cells (Figure 3A). Plasmid
integration by the ZFR in the absence of transposon
target sites was only marginally higher than background
plasmid integration in these cells (Figure 3A), suggesting
that many off-target integration events in our experiments
were the result of random plasmid integration that was
not ZFR-mediated. Nevertheless, additional studies dedi-
cated to thoroughly and quantitatively characterizing
potential off-target recombination and ZFR-DNA inter-
actions are necessary to understand the full potential of
this technology and its values relative to methods that
enhance gene targeting by homologous recombination
(37,46,47).
Commercial systems are available for cell line engineer-
ing by targeted plasmid integration. For example, the Flp-
In
TM and Jump-In
TM systems marketed by Invitrogen
make use of the Flp recombinase and phiC31 integrase,
respectively. As described above, Flp activity is not sig-
niﬁcantly greater than background levels of plasmid inte-
gration and phiC31 does not have the intrinsic sequence
speciﬁcity to recognize a single site in mammalian gen-
omes. Therefore these commercial systems account for
this lack of activity and speciﬁcity by dividing a single
expression cassette for an antibiotic resistance gene
between the genomic target site and the donor plasmid
such that only plasmid integration at the target site will
reconstitute this cassette (48,49). In contrast, we readily
recovered cells with targeted integration events by select-
ing for any plasmid incorporation into the genome by
incorporating the complete puro
R cassette on the donor
plasmid. The ability to target multiple sites within the
same cell is further evidence of the high level of ZFR ef-
ﬁciency and speciﬁcity.
The two-step strategy for genome engineering described
here (Figure 1D) will be directly useful for a variety of
applications in stem cell-based gene therapy, cell line en-
gineering, genetic engineering for biopharmaceutical pro-
duction and animal transgenesis. For example, the
polyclonal population of transposon-modiﬁed cells can
be screened for individual clones in which the ZFR
target site has been integrated into a favorable genomic
locus, as was recently demonstrated in the creation of
induced pluripotent stem cells with the piggyBac trans-
poson system (50) and the screening of lentiviral safe
harbor integration sites (51). The favorable locus may be
deﬁned by the degree of interactions with endogenous
genes, the distance to neighboring genes, lack of silencing
effects, high levels of gene expression, or other factors
(51). The ZFR could then be used to integrate transgenes
speciﬁcally at this locus in the clonal transposon-modiﬁed
population. This two-step approach is advantageous
because many different transgenes can be added to the
transposon-modiﬁed cell source in parallel, all of which
would be targeted to the same favorable locus. An analo-
gous method has been proposed for using piggyBac and
Cre recombinase for the genomic analysis of transgenic
mice (52). A similar approach has also been used with
phage integrases to engineer the genomes of cell lines, em-
bryonic stem cells and whole organisms (49,53). However
all of these systems require additional levels of selection to
compensate for insufﬁcient enzyme speciﬁcity, as dis-
cussed above. Further investigation of ZFR activity in
primary cells, embryonic stem cells, induced pluripotent
stem cells and animals will elucidate the advantages and
limitations of ZFRs in these settings.
Several other studies have investigated targeted gene
addition by fusing engineered zinc-ﬁnger proteins or
other targeted DNA-binding proteins to transposases
(14,15) and retroviral integrases (54,55). Although these
strategies have been successful in directing integration
and transposition, the vast majority of integration events
occur at locations other than the target locus.
Importantly, these fusion proteins were not engineered
to abrogate the integration activity of the parent enzyme.
Consequently, any rare targeted integration events occur
amidst many more semi-random events. This approach to
protein engineering is in contrast to our development
of ZFRs, in which the serine recombinase catalytic
domain is only active when fused to a DNA-binding
protein (40). We expect that this modular structure and
function of ZFRs contributes substantially to their precise
speciﬁcity.
Ultimately, we envision the design of ZFRs that specif-
ically target endogenous genome sequences, enabling the
direct integration of plasmid DNA into any natural locus.
The ZFR used in this study is composed of a fusion
between a designed four-ﬁnger zinc-ﬁnger protein and a
hyperactive catalytic domain of the Gin invertase from
bacteriophage Mu (40). Synthetic zinc-ﬁnger proteins can
be engineered to target almost any DNA sequence (35,36).
However, the Gin catalytic domain retains a strict
sequence speciﬁcity for its native recognition sequence in
the bacteriophage genome, thus preventing the repro-
gramming of ZFR activity solely through exchanging the
zinc-ﬁnger DNA-binding domain (40,42). To facilitate the
use of ZFRs at diverse target sequences, we have used
directed evolution to alter the sequence speciﬁcity of
ZFR catalytic domains (42,45). In particular, we have re-
cently described a structure-guided approach to directed
evolution that facilitates the engineering of domains with
high levels of activity exclusively on new targets (56). We
anticipate that this work will lead to the development of
ZFRs that integrate plasmids efﬁciently and speciﬁcally at
any genomic site of interest. This work has the potential to
transform customized genome engineering into a facile
and routine procedure.
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